146 related articles for article (PubMed ID: 36007997)
1. Progress in molecular biology and translational science addressing the needs of nano-rare patients.
Crooke ST
Prog Mol Biol Transl Sci; 2022; 190(1):127-146. PubMed ID: 36007997
[TBL] [Abstract][Full Text] [Related]
2. Important role of translational science in rare disease innovation, discovery, and drug development.
Pariser AR; Gahl WA
J Gen Intern Med; 2014 Aug; 29 Suppl 3(Suppl 3):S804-7. PubMed ID: 25029971
[TBL] [Abstract][Full Text] [Related]
3. Childhood rare lung disease in the 21st century: "-omics" technology advances accelerating discovery.
Vece TJ; Wambach JA; Hagood JS
Pediatr Pulmonol; 2020 Jul; 55(7):1828-1837. PubMed ID: 32533908
[TBL] [Abstract][Full Text] [Related]
4. Individualized Therapeutics Development for Rare Diseases: The Current Ethical Landscape and Policy Responses.
Bateman-House A; Kearns L
Nucleic Acid Ther; 2022 Apr; 32(2):111-117. PubMed ID: 34797685
[TBL] [Abstract][Full Text] [Related]
5. Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders.
Mulberg AE; Bucci-Rechtweg C; Giuliano J; Jacoby D; Johnson FK; Liu Q; Marsden D; McGoohan S; Nelson R; Patel N; Romero K; Sinha V; Sitaraman S; Spaltro J; Kessler V
Orphanet J Rare Dis; 2019 Feb; 14(1):36. PubMed ID: 30736861
[TBL] [Abstract][Full Text] [Related]
6. Improved Diagnosis and Care for Rare Diseases through Implementation of Precision Public Health Framework.
Baynam G; Bowman F; Lister K; Walker CE; Pachter N; Goldblatt J; Boycott KM; Gahl WA; Kosaki K; Adachi T; Ishii K; Mahede T; McKenzie F; Townshend S; Slee J; Kiraly-Borri C; Vasudevan A; Hawkins A; Broley S; Schofield L; Verhoef H; Groza T; Zankl A; Robinson PN; Haendel M; Brudno M; Mattick JS; Dinger ME; Roscioli T; Cowley MJ; Olry A; Hanauer M; Alkuraya FS; Taruscio D; Posada de la Paz M; Lochmüller H; Bushby K; Thompson R; Hedley V; Lasko P; Mina K; Beilby J; Tifft C; Davis M; Laing NG; Julkowska D; Le Cam Y; Terry SF; Kaufmann P; Eerola I; Norstedt I; Rath A; Suematsu M; Groft SC; Austin CP; Draghia-Akli R; Weeramanthri TS; Molster C; Dawkins HJS
Adv Exp Med Biol; 2017; 1031():55-94. PubMed ID: 29214566
[TBL] [Abstract][Full Text] [Related]
7. [Genetic mutation databases: stakes and perspectives for orphan genetic diseases].
Humbertclaude V; Tuffery-Giraud S; Bareil C; Thèze C; Paulet D; Desmet FO; Hamroun D; Baux D; Girardet A; Collod-Béroud G; Khau Van Kien P; Roux AF; des Georges M; Béroud C; Claustres M
Pathol Biol (Paris); 2010 Oct; 58(5):387-95. PubMed ID: 19954899
[TBL] [Abstract][Full Text] [Related]
8. Towards efficiency in rare disease research: what is distinctive and important?
Jia J; Shi T
Sci China Life Sci; 2017 Jul; 60(7):686-691. PubMed ID: 28639105
[TBL] [Abstract][Full Text] [Related]
9. Patients often go without effective new treatments, especially in rare disease patient populations where profit potential is limited.
Bloom BE
Contemp Clin Trials; 2011 Mar; 32(2):151-2. PubMed ID: 21238613
[No Abstract] [Full Text] [Related]
10. Addressing the Needs of Patients with Ultra-Rare Mutations One Patient at a Time: The n-Lorem Approach.
Crooke ST
Nucleic Acid Ther; 2022 Apr; 32(2):95-100. PubMed ID: 34520268
[TBL] [Abstract][Full Text] [Related]
11. [Optimising treatment for people with rare diseases].
Lund AM; Skovby F
Ugeskr Laeger; 2006 Apr; 168(15):1547-50. PubMed ID: 16640978
[TBL] [Abstract][Full Text] [Related]
12. Opportunities for developing therapies for rare genetic diseases: focus on gain-of-function and allostery.
Chen B; Altman RB
Orphanet J Rare Dis; 2017 Apr; 12(1):61. PubMed ID: 28412959
[TBL] [Abstract][Full Text] [Related]
13. Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies.
Lekstrom-Himes J; Brooks PJ; Koeberl DD; Brower A; Goldenberg A; Green RC; Morris JA; Orsini JJ; Yu TW; Augustine EF
Am J Med Genet C Semin Med Genet; 2023 Mar; 193(1):30-43. PubMed ID: 36738469
[TBL] [Abstract][Full Text] [Related]
14. The long tail and rare disease research: the impact of next-generation sequencing for rare Mendelian disorders.
Shen T; Lee A; Shen C; Lin CJ
Genet Res (Camb); 2015 Sep; 97():e15. PubMed ID: 26365496
[TBL] [Abstract][Full Text] [Related]
15. Addressing challenges in the diagnosis and treatment of rare genetic diseases.
Boycott KM; Ardigó D
Nat Rev Drug Discov; 2018 Mar; 17(3):151-152. PubMed ID: 29242613
[TBL] [Abstract][Full Text] [Related]
16. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
17. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
18. Bridging the Gap between Health and Social Care for Rare Diseases: Key Issues and Innovative Solutions.
Castro R; Senecat J; de Chalendar M; Vajda I; Dan D; Boncz B;
Adv Exp Med Biol; 2017; 1031():605-627. PubMed ID: 29214594
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
